EGFR and glioblastoma: A recent clinical study showed that after initiation of PD-1 inhibitor (pembrolizumab or nivolumab) for recurrent GBM patients with EGFR amplification, the median OS was 7 months compared to 18 months for those without EGFR amplification (16).